Company Description
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.
The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2012 |
| IPO Date | Dec 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 562 |
| CEO | Carl Hansen |
Contact Details
Address: 150 W 4th Avenue Vancouver, BC V5Y 1G6 Canada | |
| Phone | 604 559 9005 |
| Website | abcellera.com |
Stock Details
| Ticker Symbol | ABCL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 1703057 |
| CUSIP Number | 00288U106 |
| ISIN Number | CA00288U1066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carl L.G. Hansen Ph.D. | Chief Executive Officer, President and Chairperson |
| Andrew Booth M.B.A. | Chief Financial Officer |
| Dr. Veronique Lecault Ph.D. | Chief Technology Officer and Director |
| Tryn T. Stimart Esq., J.D., M.Sc. | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 6, 2026 | 8-K | Current Report |
| Jun 17, 2026 | 8-K | Current Report |
| Jun 12, 2026 | 8-K | Current Report |
| Jun 5, 2026 | 8-K | Current Report |
| May 11, 2026 | 10-Q | Quarterly Report |
| May 11, 2026 | 8-K | Current Report |
| May 7, 2026 | SCHEDULE 13G/A | Filing |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |